Tyrosine kinase inhibitors and multidrug resistance proteins: Interactions and biological consequences

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 2, 2010, Pages 335-346

  Azzariti, Amalia ^a   Porcelli, Letizia ^a   Simone, Grazia M ^a   Quatrale, Anna E ^a   Colabufo, Nicola A ^b   Berardi, Francesco ^b   Perrone, Roberto ^b   Zucchetti, Massimo ^c   D'Incalci, Maurizio ^c   Xu, Jian Ming ^d   Paradiso, Angelo ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Beijing 307 Hospital   (China)

Author keywords

BCRP; Gefitinib; P glycoprotein; Resistance; Vandetanib

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; GEFITINIB; GLYCOPROTEIN P; IRINOTECAN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; VANDETANIB; VERAPAMIL;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL STRAIN; CELL STRAIN CACO 2; CELL STRAIN HT29; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL LINE; CELL LINE, TUMOR; DOGS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; TIME FACTORS;

EID: 71349086685     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1039-0     Document Type: Article

References (37)

1. H Zhong JP Bowen 2007 Molecular design and clinical development of VEGFR kinase inhibitors Curr Top Med Chem 7 1379 1393 10.2174/156802607779318334 1:CAS:528:DC%2BD2sXht1SmtbrE 17692027 (Pubitemid 46062397)
2. MF Press HJ Lenz 2007 EGFR, HER2 and VEGF pathways: validated targets for cancer treatment Drugs 67 2045 2075 10.2165/00003495-200767140-00006 1:CAS:528:DC%2BD2sXhtleqsrrF 17883287
3. M Ono M Kuwano 2006 Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs Clin Cancer Res 12 7242 7251 10.1158/1078-0432.CCR-06-0646 1:CAS:528:DC%2BD28XhtlCrtr7M 17189395 (Pubitemid 46095395)
4. S Sebastian J Settleman SJ Reshkin A Azzariti A Bellizzi A Paradiso 2006 The complexity of targeting EGFR signalling in cancer: from expression to turnover Biochim Biophys Acta 1766 120 139 1:CAS:528:DC%2BD28XotVyru7w%3D 16889899
5. G Giannelli A Azzariti E Fransvea L Porcelli S Antonaci A Paradiso 2004 Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells Br J Cancer 91 1964 1969 10.1038/sj.bjc.6602231 1:CAS:528:DC%2BD2cXhtVSqs7nK 15545972 (Pubitemid 40065526)
6. G Giannelli A Azzariti C Sgarra L Porcelli S Antonaci A Paradiso 2006 ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells Biochem Pharmacol 71 479 485 10.1016/j.bcp.2005.11.005 1:CAS:528:DC%2BD28XksVWnsg%3D%3D 16332356 (Pubitemid 43077082)
7. G Giannelli C Sgarra L Porcelli A Azzariti S Antonaci A Paradiso 2008 EGFR and VEGFR as potential target for biological therapies in HCC cells Cancer Lett 262 257 264 10.1016/j.canlet.2007.12.001 1:CAS:528:DC%2BD1cXjtlWgsLk%3D 18248788
8. S Hoffmann S Gläser A Wunderlich, et al. 2006 Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors-a novel antiproliferative/ antiangiogenic strategy in thyroid cancer Langenbecks Arch Surg 391 589 596 10.1007/s00423-006-0104-y 1:STN:280:DC%2BD28njsFGqsA%3D%3D 17053904 (Pubitemid 44657740)
9. A Azzariti L Porcelli G Gatti A Nicolin A Paradiso 2008 Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells Biochem Pharmacol 75 1035 1044 10.1016/j.bcp.2007.11.018 1:CAS:528:DC%2BD1cXhvVWgsbg%3D 18191814
10. M Leggas JC Panetta Y Zhuang, et al. 2006 Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo Cancer Res 66 4802 4807 10.1158/0008-5472.CAN-05-2915 1:CAS:528:DC%2BD28XjvF2kt78%3D 16651435
11. A Azzariti L Porcelli JM Xu GM Simone A Paradiso 2006 Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects World J Gastroenterol 12 5140 5147 1:CAS:528: DC%2BD28XhtVeqtb3E 16937523
12. Z Shi XX Peng IW Kim, et al. 2007 Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance Cancer Res 67 11012 11020 10.1158/0008-5472.CAN-07-2686 1:CAS:528:DC%2BD2sXhtlSlsLrF 18006847 (Pubitemid 350145931)
13. K Yanase S Tsukahara S Asada E Ishikawa Y Imai Y Sugimoto 2004 Gefitinib reverses breast cancer resistance protein-mediated drug resistance Mol Cancer Ther 3 1119 1125 1:CAS:528:DC%2BD2cXnsFajtL8%3D 15367706
14. Y Nakamura M Oka H Soda, et al. 2005 Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance Cancer Res 65 1541 1546 10.1158/0008-5472.CAN-03-2417 1:CAS:528:DC%2BD2MXhsFKqtb8%3D 15735043 (Pubitemid 40270183)
15. NB Elkind Z Szentpétery A Apáti, et al. 2005 Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) Cancer Res 65 1770 1777 10.1158/0008-5472.CAN-04-3303 1:CAS:528:DC%2BD2MXitVOjsb4%3D 15753373 (Pubitemid 40478603)
16. C Lemos G Jansen GJ Peters 2008 Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors Br J Cancer 98 857 862 10.1038/sj.bjc.6604213 1:CAS:528:DC%2BD1cXivVOgt7o%3D 18253130 (Pubitemid 351341599)
17. A Italiano B Besse D Planchard JC Soria 2007 Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives Bull Cancer 94 7 Suppl F177 F188 1:CAS:528:DC%2BD1cXkvVSiug%3D%3D 17964994
18. R O'Connor 2007 The pharmacology of cancer resistance Anticancer Res 27 1267 1272 17593618
19. JP Gillet T Efferth J Remacle 2007 Chemotherapy-induced resistance by ATP-binding cassette transporter genes Biochim Biophys Acta 1775 237 262 1:CAS:528:DC%2BD2sXmsFKmtLY%3D 17572300
20. A Azzariti NA Colabufo F Berardi, et al. 2006 Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer Mol Cancer Ther 5 1807 1816 10.1158/1535-7163.MCT-05-0402 1:CAS:528:DC%2BD28XnslWksbo%3D 16891467 (Pubitemid 44323249)
21. T Kitazaki M Oka Y Nakamura, et al. 2005 Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells Lung Cancer 49 337 343 10.1016/j.lungcan.2005.03.035 15955594 (Pubitemid 41139146)
22. Y Mi L Lou 2007 ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein Br J Cancer 97 934 940 10.1038/sj.bjc.6603985 1:CAS:528:DC%2BD2sXhtFSnurnK 17912240 (Pubitemid 47519322)
23. A Azzariti JM Xu L Porcelli A Paradiso 2004 The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839) Biochem Pharmacol 68 135 144 10.1016/j.bcp.2004.03.014 1:CAS:528:DC%2BD2cXkslWksrw%3D 15183125 (Pubitemid 38746549)
24. NA Colabufo F Berardi M Cantore, et al. 2008 4-Biphenyl and 2-naphthyl substituted 6, 7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators Bioorg Med Chem 16 3732 3743 10.1016/j.bmc.2008.01.055 1:CAS:528:DC%2BD1cXks1Gqtrw%3D 18276145
25. J Rautio JE Humphreys LO Webster, et al. 2006 In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates Drug Metab Dispos 34 786 792 10.1124/dmd.105.008615 1:CAS:528:DC%2BD28Xks1Sksbo%3D 16455806
26. L Kangas M Grönroos AL Nieminem 1984 Bioluminescence of cellular ATP: a new method for evaluating agents in vitro Med Biol 62 338 343 1:CAS:528:DyaL2MXltFGmsbw%3D 6543460
27. ME Taub L Podila I Almeida 2005 Functional assessment of multiple P-glycoprotein (P-gp) probe substrate: influence of cell line and modulator concentration on P-gp activity Drug Metab Dispos 33 1679 1687 10.1124/dmd.105.005421 1:CAS:528:DC%2BD2MXhtFOru73E 16093365 (Pubitemid 41539967)
28. NA Colabufo F Berardi M Cantore, et al. 2008 Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives Bioorg Med Chem 16 362 373 10.1016/j.bmc.2007.09.039 1:CAS:528:DC%2BD1cXlvFSltQ%3D%3D 17936633
29. JW Polli SA Wring JE Humphreys, et al. 2001 Rational use of in vitro P-glycoprotein assays in drug discovery J Pharmacol Exp Ther 299 620 628 1:CAS:528:DC%2BD3MXnvV2qt78%3D 11602674
30. X Wang ME Morris 2007 Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2 Drug Metab Dispos 35 268 274 10.1124/dmd.106.011684 1:CAS:528:DC%2BD2sXhvVKrsL4%3D 17093006 (Pubitemid 46148740)
31. Q Wang R Strab P Kardos, et al. 2008 Application and limitation of inhibitors in drug-transporter interactions studies Int J Pharm 356 12 18 10.1016/j.ijpharm.2007.12.024 1:CAS:528:DC%2BD1cXlsFClurk%3D 18272304
32. JP Lopez J Wang-Rodriguez C Chang, et al. 2007 Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines Arch Otolaryngol Head Neck Surg 133 1022 1027 10.1001/archotol.133.10.1022 17938326 (Pubitemid 47607585)
33. S Nagashima H Soda M Oka, et al. 2006 BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer Cancer Chemother Pharmacol 58 594 600 10.1007/s00280-006-0212-y 1:CAS:528:DC%2BD28Xns1SmsLs%3D 16520985 (Pubitemid 44167384)
34. H Liu D Cheng AK Weichel, et al. 2006 Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells Int J Oncol 29 1237 1246 1:CAS:528:DC%2BD28Xht1Wjs7jP 17016657
35. SR Wedge DJ Ogilvie M Dukes, et al. 2002 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645 4655 1:CAS:528:DC%2BD38XmsVShsL8%3D 12183421
36. AE Wakeling SP Guy JR Woodburn, et al. 2002 ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res 62 5749 5754 1:CAS:528:DC%2BD38XotFyktr8%3D 12384534
37. J Usuda T Ohira Y Suga, et al. 2007 Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer Lung Cancer 58 296 299 10.1016/j.lungcan.2007.05.019 1:STN:280:DC%2BD2srpslSksA%3D%3D 17618705 (Pubitemid 47513247)